Table 1.

Selected Baseline Characteristics of the Participants in Trial 1.^*

Characteristic	Nevirapine (N = 121)	Ritonavir-Boosted Lopinavir (N = 120)	Total (N = 241)
Age at randomization — yr
Median	30	31	31
10th–90th percentile	24–37	24–38	24–37
Black race — no. (%)†	121 (100)	120 (100)	241 (100)
CD4+ count at baseline
Median — cells/mm3	141	138	139
10th–90th percentile — cells/mm3	47–202	55–212	48–208
<50 cells/mm3 — no. (%)	14 (12)	11 (9)	25 (10)
HIV-1 RNA
Median — log10 copies/ml	5.20	5.14	5.15
10th–90th percentile — log10 copies/ml	4.26–5.84	4.19–5.88	4.24–5.88
≥750,000 copies/ml — no. (%)	11 (9)	15 (12)	26 (11)
WHO HIV clinical stage — no. (%)
I	44 (36)	56 (47)	100 (41)
II	42 (35)	38 (32)	80 (33)
III	30 (25)	25 (21)	55 (23)
IV	5 (4)	1 (1)	6 (2)
Hepatitis B surface antigen
Positive — no. (%)	9 (8)	5 (4)	14 (6)
Not determined — no.	2	0	2
Interval since most recent exposure to single-dose NVP
Median — mo	16	17	17
10th–90th percentile — mo	7–49	7–41	7–45
≥6 to <12 mo — no. (%)	41 (34)	37 (31)	78 (32)
≥12 to <24 mo — no. (%)	46 (38)	52 (43)	98 (41)
≥24 mo — no. (%)	34 (28)	31 (26)	65 (27)
No. of previous exposures to single-dose NVP — no. (%)
1	115 (95)	114 (95)	229 (95)
2	6 (5)	4 (3)	10 (4)
3	0	2 (2)	2 (1)
Self-reported prior receipt of single-dose NVP — no. (%)	121 (100)	120 (100)	241 (100)
Written documentation of prior nevirapine exposure — no. (%)	86 (71)	90 (75)	176 (73)
Previous zidovudine exposure — no. (%)	13 (11)	12 (10)	25 (10)
HIV subtype — no. (%)
A1	18 (15)	15 (13)	33 (14)
C	87 (73)	86 (72)	173 (72)
D	6 (5)	9 (8)	15 (6)
A2D	1 (1)	0	1 (0.4)
Complex recombination	8 (7)	9 (8)	17 (7)
Test result not available — no.	1	1	2

^*HIV denotes human immunodeficiency virus, NVP nevirapine, and WHO World Health Organization.

^†Race was reported by the investigators.